Liliana Sedova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Liliana Sedova has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Jiří Štolfa
Institute of Rheumatology
6 shared publications - Karel Pavelka
Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Czech Republic
6 shared publications - Jiří Vencovský
Institute of Rheumatology, Research Department, and Department of Rheumatology, 1st Medical Faculty, Charles University, Prague, Czech Republic
5 shared publications - Aleksi Sedo
Laboratory of Cancer Cell Biology, Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic
3 shared publications Tomáš Doležal
Institute of Health Economics and Technology Assessment o.p.s., Prague, Czech Republic; Department of Pharmacology, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
3 shared publicationsAlena Petříková
Faculty of Pharmacy, Department of Social and Clinical Pharmacy, Charles University, Prague, Czech Republic
2 shared publications
Latest Publications
- 21 November 2017
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 11 (3) , 329-340
Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis
Clinical trials and observational studies lacking measures of health-related quality of life (QoL) are often inapplicable when conducting cost-effectiveness analyses using quality-adjusted life-years (QALYs). The only solution is to map QoL ex post from additionally collected clinical outcomes and generic QoL instruments. Nonetheless, mapping studies are absent in psoriatic arthritis (PsA).
- 21 November 2017
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 11 (3) , 329-340
Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis
Clinical trials and observational studies lacking measures of health-related quality of life (QoL) are often inapplicable when conducting cost-effectiveness analyses using quality-adjusted life-years (QALYs). The only solution is to map QoL ex post from additionally collected clinical outcomes and generic QoL instruments. Nonetheless, mapping studies are absent in psoriatic arthritis (PsA).
- 6 December 2016
- Vol. 155 (6) , 285-293
[15 years experience with biological therapy of inflammatory rheumatic diseases in Czech national register ATTRA].
The publication is summarizing application of biological DMARDs in autoimmune inflammatory rheumatic diseases.Up to now conventional therapy, which for example in rheumatoid arthritis was application of methotrexate (MTx) in combination with glucocorticoids, was effective, but the remission as a target was achieved in small proportion of patients and also there was little effect on structural progression of diseases. Biological therapy was great advance because response was achieved in ¾ patients who failed MTx. At present time 8 biological drugs are available. 5 are inhibitors of TNFα and 3 have different move of action. In psoriatic arthritis are beside TNF blockers available blocker of IL 17 (secukinumab, ustekinumab, apremilast). For ankylosing spondylitis is registered secukinumab.Anti-TNF therapy is relative safe but rarely serious adverse events can occur. The most important are serious infections, opportunistic infections and tuberculosis. Other adverse event includes allergic reactions and local intolerance. Increase incidence of lymphomas was not confirmed. There is probably minimal increased risk of skin melanoma and non-melanoma tumors. Benefit/risk ratio is still very positive.National registry of biological therapy ATTRA was founded 15 years ago and includes patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. In June 2016 over all 6800 patients with those diagnoses was included and actually 5194 have been treated. In registry patients are regularly followed for activity, efficacy of the drug and other events. Results of registry are sent payers for evaluations of pharmacologic parameters.
- 6 December 2016
- Vol. 155 (6) , 285-293
[15 years experience with biological therapy of inflammatory rheumatic diseases in Czech national register ATTRA].
The publication is summarizing application of biological DMARDs in autoimmune inflammatory rheumatic diseases.Up to now conventional therapy, which for example in rheumatoid arthritis was application of methotrexate (MTx) in combination with glucocorticoids, was effective, but the remission as a target was achieved in small proportion of patients and also there was little effect on structural progression of diseases. Biological therapy was great advance because response was achieved in ¾ patients who failed MTx. At present time 8 biological drugs are available. 5 are inhibitors of TNFα and 3 have different move of action. In psoriatic arthritis are beside TNF blockers available blocker of IL 17 (secukinumab, ustekinumab, apremilast). For ankylosing spondylitis is registered secukinumab.Anti-TNF therapy is relative safe but rarely serious adverse events can occur. The most important are serious infections, opportunistic infections and tuberculosis. Other adverse event includes allergic reactions and local intolerance. Increase incidence of lymphomas was not confirmed. There is probably minimal increased risk of skin melanoma and non-melanoma tumors. Benefit/risk ratio is still very positive.National registry of biological therapy ATTRA was founded 15 years ago and includes patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. In June 2016 over all 6800 patients with those diagnoses was included and actually 5194 have been treated. In registry patients are regularly followed for activity, efficacy of the drug and other events. Results of registry are sent payers for evaluations of pharmacologic parameters.
- 24 June 2016
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 17 (2) , 203-211
Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis
Aim: To map health-related quality of life (Qol) with clinical parameters BASFI and ASDAS-CRP measure, and other covariates. Methods: Our prospective multicenter non-interventional observation study of ankylosing spondylitis (AS) collected data about QoL and clinical outcomes on the initial and four subsequent visits. We employed simple linear regression analysis of a cross-sectional dataset, and fixed effect, random effect and pooled linear regression of a longitudinal dataset. Results: We showed that BASFI and ASDAS-CRP are very strong, robust predictors of EQ-5D utilities in all regression specifications together with sex (female), invalidity, and activity impairment. Additionally, the longitudinal regression analysis showed that a fixed effect model may be a viable alternative to the most commonly used random effect model or pooled linear regression due to the nature of our dataset. Conclusion: This is one of the first studies using a fixed effect model in longitudinal patient-level data, although, this method has been widely used in economics.
- 24 June 2016
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 17 (2) , 203-211
Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis
Aim: To map health-related quality of life (Qol) with clinical parameters BASFI and ASDAS-CRP measure, and other covariates. Methods: Our prospective multicenter non-interventional observation study of ankylosing spondylitis (AS) collected data about QoL and clinical outcomes on the initial and four subsequent visits. We employed simple linear regression analysis of a cross-sectional dataset, and fixed effect, random effect and pooled linear regression of a longitudinal dataset. Results: We showed that BASFI and ASDAS-CRP are very strong, robust predictors of EQ-5D utilities in all regression specifications together with sex (female), invalidity, and activity impairment. Additionally, the longitudinal regression analysis showed that a fixed effect model may be a viable alternative to the most commonly used random effect model or pooled linear regression due to the nature of our dataset. Conclusion: This is one of the first studies using a fixed effect model in longitudinal patient-level data, although, this method has been widely used in economics.
- Open Access
- 3 December 2015
- Published by Palacky University Olomouc in Biomedical Papers
- Vol. 159 (4) , 562-568
Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris
Psoriasis vulgaris (PV) is complicated in up to 40% patients by the inflammatory joint disease psoriatic arthritis (PsA). Neither the aetiology of the arthritis nor specific laboratory markers for its disease activity have been clearly elucidated. Prolactin (PRL) acts as a cytokine with immunomodulatory functions and plays a role in skin and joint biology. The results on PRL however as a marker are unclear. The aim of this study was to confirm whether serum PRL levels reflect systemic complications of PV, like inflammatory joint disease and/or can serve as a marker of disease activity in both cases. A total of 70 patients with PV without arthritis and 40 patients suffering from PsA were included. In all patients, we determined skin disease activity according to the PASI index and in PsA, active disease assessed as swollen or tender joints. The control group included 27 age and sex matched healthy individuals. The concentration of PRL in the serum was measured by immunoradiometric assays. The PRL serum levels were significantly increased in PsA patients (299.2±28.29 mIU/L) compared to PV only patients (201.4.2±11.72 mIU/L), P = 0.0003 and healthy individuals (198.2±15.31 mIU/L), P = 0.007. The serum PRL levels in PsA with active disease 336.8±42.50 (mIU/L) were higher than in PV and controls, P < 0.0001 and P = 0.002 respectively. In PV only patients, there was no correlation between PASI and PRL levels. Our results showed that PRL serum levels are a marker of active arthritis in PsA and reflects systemic complication rather than local skin activity.
- 3 December 2015
- Published by Palacky University Olomouc in Biomedical Papers
- Vol. 159 (4) , 562-568
Open AccessElevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris
Psoriasis vulgaris (PV) is complicated in up to 40% patients by the inflammatory joint disease psoriatic arthritis (PsA). Neither the aetiology of the arthritis nor specific laboratory markers for its disease activity have been clearly elucidated. Prolactin (PRL) acts as a cytokine with immunomodulatory functions and plays a role in skin and joint biology. The results on PRL however as a marker are unclear. The aim of this study was to confirm whether serum PRL levels reflect systemic complications of PV, like inflammatory joint disease and/or can serve as a marker of disease activity in both cases. A total of 70 patients with PV without arthritis and 40 patients suffering from PsA were included. In all patients, we determined skin disease activity according to the PASI index and in PsA, active disease assessed as swollen or tender joints. The control group included 27 age and sex matched healthy individuals. The concentration of PRL in the serum was measured by immunoradiometric assays. The PRL serum levels were significantly increased in PsA patients (299.2±28.29 mIU/L) compared to PV only patients (201.4.2±11.72 mIU/L), P = 0.0003 and healthy individuals (198.2±15.31 mIU/L), P = 0.007. The serum PRL levels in PsA with active disease 336.8±42.50 (mIU/L) were higher than in PV and controls, P < 0.0001 and P = 0.002 respectively. In PV only patients, there was no correlation between PASI and PRL levels. Our results showed that PRL serum levels are a marker of active arthritis in PsA and reflects systemic complication rather than local skin activity.
- Open Access
- 9 September 2015
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 16 (1) , 1-7
Intraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity
Dipeptidyl peptidase-IV (DPP-IV) is suggested to contribute to the pathogenesis of several autoimmune diseases. The aim of this study was to evaluate the association of DPP-IV presence in blood plasma and mononuclear cells with the disease activity in rheumatoid arthritis (RA). Patients with active RA (n = 27) were examined at the study enrolment and a follow-up examination was performed after the regression of the joint effusions and at least 6 months after the first investigation. The control group comprised patients with a noninflammatory joint disease, i.e. osteoarthritis (OA; n = 15). The DPP-IV-like enzymatic activity was measured by a kinetic fluorimetric method, the concentration of DPP-IV in the blood plasma was determined using ELISA and the expression of DPP-IV in leukocytes was assayed by flow cytometry. Blood plasma DPP-IV-like enzymatic activity (median ± SD 220.15 ± 83.6 pkat/mL in RA vs. 376.9 ± 144.9 pkat/mL in OA, p < 0.001) and concentrations (median ± SD 465.1 ± 215.6 ng/mL in RA vs. 953.3 ± 368.4 ng/mL in OA, p < 0.001) were lower in patients with active RA compared to OA. In RA patients, the blood plasma DPP-IV-like enzymatic activity negatively correlated with the CRP concentration (r = −0.39, p = 0.044). No significant differences were observed in the DPP-IV-like enzymatic activity and DPP-IV expression in blood mononuclear cells between the RA and OA groups. At follow-up, 18 RA patients had a less active disease as demonstrated by an improved DAS28 score. In this group, comparison of the entry and the follow-up values in individual patients revealed an increase of the blood plasma DPP-IV-like enzymatic activity (median ± SD 141 ± 46 % of the patient’s entry values, p = 0.011) and DPP-IV concentration (median ± SD 168 ± 25 %, of the patient’s entry values, p = 0.033). In contrast to the blood plasma, the DPP-IV expression in blood mononuclear cells was reduced in these patients as evidenced by a decrease in the cell surface DPP-IV-like enzymatic activity as well as the median fluorescence intensity of DPP-IV staining in lymphocytes (median ± SD 66 ± 56 %, p = 0.018 and 63 ± 31 % of the patient’s entry values, p = 0.005, respectively). The association between RA activity and the changes in blood plasma and blood mononuclear cell DPP-IV in individual patients supports the possible relationship of DPP-IV to RA pathophysiology.
- 9 September 2015
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 16 (1) , 1-7
Open AccessIntraindividual changes of dipeptidyl peptidase-IV in peripheral blood of patients with rheumatoid arthritis are associated with the disease activity
Dipeptidyl peptidase-IV (DPP-IV) is suggested to contribute to the pathogenesis of several autoimmune diseases. The aim of this study was to evaluate the association of DPP-IV presence in blood plasma and mononuclear cells with the disease activity in rheumatoid arthritis (RA). Patients with active RA (n = 27) were examined at the study enrolment and a follow-up examination was performed after the regression of the joint effusions and at least 6 months after the first investigation. The control group comprised patients with a noninflammatory joint disease, i.e. osteoarthritis (OA; n = 15). The DPP-IV-like enzymatic activity was measured by a kinetic fluorimetric method, the concentration of DPP-IV in the blood plasma was determined using ELISA and the expression of DPP-IV in leukocytes was assayed by flow cytometry. Blood plasma DPP-IV-like enzymatic activity (median ± SD 220.15 ± 83.6 pkat/mL in RA vs. 376.9 ± 144.9 pkat/mL in OA, p < 0.001) and concentrations (median ± SD 465.1 ± 215.6 ng/mL in RA vs. 953.3 ± 368.4 ng/mL in OA, p < 0.001) were lower in patients with active RA compared to OA. In RA patients, the blood plasma DPP-IV-like enzymatic activity negatively correlated with the CRP concentration (r = −0.39, p = 0.044). No significant differences were observed in the DPP-IV-like enzymatic activity and DPP-IV expression in blood mononuclear cells between the RA and OA groups. At follow-up, 18 RA patients had a less active disease as demonstrated by an improved DAS28 score. In this group, comparison of the entry and the follow-up values in individual patients revealed an increase of the blood plasma DPP-IV-like enzymatic activity (median ± SD 141 ± 46 % of the patient’s entry values, p = 0.011) and DPP-IV concentration (median ± SD 168 ± 25 %, of the patient’s entry values, p = 0.033). In contrast to the blood plasma, the DPP-IV expression in blood mononuclear cells was reduced in these patients as evidenced by a decrease in the cell surface DPP-IV-like enzymatic activity as well as the median fluorescence intensity of DPP-IV staining in lymphocytes (median ± SD 66 ± 56 %, p = 0.018 and 63 ± 31 % of the patient’s entry values, p = 0.005, respectively). The association between RA activity and the changes in blood plasma and blood mononuclear cell DPP-IV in individual patients supports the possible relationship of DPP-IV to RA pathophysiology.
- 1 September 2014
- Published by Elsevier in Value in Health Regional Issues
- Vol. 4, 100-106
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis
- 1 September 2014
- Published by Elsevier in Value in Health Regional Issues
- Vol. 4, 100-106
Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis
- 1 September 2014
- Published by Elsevier in Value in Health Regional Issues
- Vol. 4, 75-81
Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of-Illness Study Based on Disease Severity
- 1 September 2014
- Published by Elsevier in Value in Health Regional Issues
- Vol. 4, 75-81
Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of-Illness Study Based on Disease Severity
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 407
FRI0071 Effect of Biological Therapy on Fatigue in Patients with Rheumatoid Arthritis
Background Fatigue is a frequent symptom among patients with rheumatoid arthritis (RA) and contributes to decreased quality of life in these patients [1].There are various questionnaires to assess fatigue in rheumatic diseases among them the vitality scale from SF-36 [2]. Objectives To assess the effect of one year of biologic therapy on fatigue of RA patients and correlate it with other parameters of the disease like laboratory and clinical activity, function and the quality of life. Methods 1029 patients from the Czech Registry of patients with RA (ATTRA), who had been treated with first line biological therapy for a minimum of 1 year, were analyzed. Following parameters were assessed at the start of biological therapy and 12 months after: Fatigue was assessed using the ninth item from SF-36, question: “Did you feel tired during past 4 weeks?” Humoral activity according to ESR and CRP, clinical activity was assessed by No. of tender and swollen joints and by patient's disease activity assessment (VAS100mm) and DAS28-CRP, function by HAQ and quality of life by EuroQOL and further items of SF-36 (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health). Improvement, disease activity, function and quality of life after 12 month of biological therapy was assessed by counts (percentages) and median (interquartile range) when describing categorical and continuous variables respectively. Significance of improvement after 12 months and significance of association between fatigue improvement and improvement in other parameters of disease was assessed using p-value of Wilcoxon Signed Ranks Test and Kruskal-Wallis H Test, respectively. Results 1.After 12 months there is a significant improvement of fatigue as well as parameters of activity, function and quality of life (pConclusions One year biological therapy of RA leads to significant improvement not only of clinical parameters of the disease, but also to significant improvement of fatigue. The improvement of fatigue strongly correlates with the improvement of clinical and humoral activity, function and quality of life. Absence of correlation with the No. of swollen joint is no clear and requires further clarification. References Suurmeijer TP, Walz M, MoumT, et al. Quality of life profiles in the first years of rheumatoid arthritis. Arthritis Rheum 2001;45:111-21. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). Conceptual framework and item selection. Med Care 19925;30:473-83 Acknowledgements Aknowledgment: Supported by the Research program of the Ministry of health of Czech Republic: IGA MZ CR: No. 000 000 23728 Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3842
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 407
FRI0071 Effect of Biological Therapy on Fatigue in Patients with Rheumatoid Arthritis
Background Fatigue is a frequent symptom among patients with rheumatoid arthritis (RA) and contributes to decreased quality of life in these patients [1].There are various questionnaires to assess fatigue in rheumatic diseases among them the vitality scale from SF-36 [2]. Objectives To assess the effect of one year of biologic therapy on fatigue of RA patients and correlate it with other parameters of the disease like laboratory and clinical activity, function and the quality of life. Methods 1029 patients from the Czech Registry of patients with RA (ATTRA), who had been treated with first line biological therapy for a minimum of 1 year, were analyzed. Following parameters were assessed at the start of biological therapy and 12 months after: Fatigue was assessed using the ninth item from SF-36, question: “Did you feel tired during past 4 weeks?” Humoral activity according to ESR and CRP, clinical activity was assessed by No. of tender and swollen joints and by patient's disease activity assessment (VAS100mm) and DAS28-CRP, function by HAQ and quality of life by EuroQOL and further items of SF-36 (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health). Improvement, disease activity, function and quality of life after 12 month of biological therapy was assessed by counts (percentages) and median (interquartile range) when describing categorical and continuous variables respectively. Significance of improvement after 12 months and significance of association between fatigue improvement and improvement in other parameters of disease was assessed using p-value of Wilcoxon Signed Ranks Test and Kruskal-Wallis H Test, respectively. Results 1.After 12 months there is a significant improvement of fatigue as well as parameters of activity, function and quality of life (pConclusions One year biological therapy of RA leads to significant improvement not only of clinical parameters of the disease, but also to significant improvement of fatigue. The improvement of fatigue strongly correlates with the improvement of clinical and humoral activity, function and quality of life. Absence of correlation with the No. of swollen joint is no clear and requires further clarification. References Suurmeijer TP, Walz M, MoumT, et al. Quality of life profiles in the first years of rheumatoid arthritis. Arthritis Rheum 2001;45:111-21. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). Conceptual framework and item selection. Med Care 19925;30:473-83 Acknowledgements Aknowledgment: Supported by the Research program of the Ministry of health of Czech Republic: IGA MZ CR: No. 000 000 23728 Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3842
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 1051-1052
AB0749 Effect of Biological Therapy on Fatigue on Patients with Psoriatic Arthritis
Background Fatigue is a frequent symptom among patients with psoriatic arthritis (PsA). Occurrence in literature is given in up to 45% of patients [1] and changes in fatigue were shown to reflect changes in disease activity [2] and improve with treatment with adalimumab [3] Objectives To assess the effect of one year biologic therapy on fatigue in PsA patients and correlate it with other parameters of the disease like laboratory and clinical activity, function and the quality of life. Methods 265 pats. from the Czech register of patients with PsA (ATTRA), who had been treated with first line biological therapy for a minimum of 1 year were analyzed. Following parameters were assessed at the start of biological therapy and 12 months after. Fatigue was assessed using the ninth item from SF-36, question “did you feel tired during past 4 weeks”? Laboratory activity according to ESR and CRP, clinical activity was assessed by No. of tender (out of 68) and swollen (out of 66) joints and by phycian's PsA assessment (VAS100mm), function by HAQ and quality of life by EuroQOL and further items of SF-36 (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health). Improvement, disease activity, function and quality of life after 12 month of biological therapy was assessed by counts (percentages) and median (interquartile range) when describing categorical and continuous variables respectively. Significance of improvement after 12 months and significance of association between fatigue improvement and improvement in other parameters of disease was assessed using p-value of Wilcoxon Signed Ranks Test and Kruskal-Wallis H Test, respectively. Results After 12 months there is a significant improvement of fatigue, as well as parameters of activity, function and quality of life (pConclusions One year biological therapy of PsA leads to significant improvement not only of clinical parameters of the disease, but also to significant improvement of fatigue. The improvement of fatigue strongly correlates with the improvement of function and quality of life, less (but still significantly) with clinical parameters and surprisingly not with humoral activity. References Schentag CT, Beaton M, Rahman P et al. Fatigue in psoriatic arthritis (PsA). J Rheumatol 1999;26:1627 Schentag C, Gladman DD. Changes in fatigue in psoriatic arthritis, disease activity or fibromyalgia. Arthritis Rheum 2002;46(Suppl 9):S424 Mease PJ, Gladman DD, RitchlinCT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 2005;52:3297-89 Acknowledgements Supported by the Research program of the Ministry of health of Czech Republic: IGA MZ CR: No. 000 000 23728. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3911
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 1051-1052
AB0749 Effect of Biological Therapy on Fatigue on Patients with Psoriatic Arthritis
Background Fatigue is a frequent symptom among patients with psoriatic arthritis (PsA). Occurrence in literature is given in up to 45% of patients [1] and changes in fatigue were shown to reflect changes in disease activity [2] and improve with treatment with adalimumab [3] Objectives To assess the effect of one year biologic therapy on fatigue in PsA patients and correlate it with other parameters of the disease like laboratory and clinical activity, function and the quality of life. Methods 265 pats. from the Czech register of patients with PsA (ATTRA), who had been treated with first line biological therapy for a minimum of 1 year were analyzed. Following parameters were assessed at the start of biological therapy and 12 months after. Fatigue was assessed using the ninth item from SF-36, question “did you feel tired during past 4 weeks”? Laboratory activity according to ESR and CRP, clinical activity was assessed by No. of tender (out of 68) and swollen (out of 66) joints and by phycian's PsA assessment (VAS100mm), function by HAQ and quality of life by EuroQOL and further items of SF-36 (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health). Improvement, disease activity, function and quality of life after 12 month of biological therapy was assessed by counts (percentages) and median (interquartile range) when describing categorical and continuous variables respectively. Significance of improvement after 12 months and significance of association between fatigue improvement and improvement in other parameters of disease was assessed using p-value of Wilcoxon Signed Ranks Test and Kruskal-Wallis H Test, respectively. Results After 12 months there is a significant improvement of fatigue, as well as parameters of activity, function and quality of life (pConclusions One year biological therapy of PsA leads to significant improvement not only of clinical parameters of the disease, but also to significant improvement of fatigue. The improvement of fatigue strongly correlates with the improvement of function and quality of life, less (but still significantly) with clinical parameters and surprisingly not with humoral activity. References Schentag CT, Beaton M, Rahman P et al. Fatigue in psoriatic arthritis (PsA). J Rheumatol 1999;26:1627 Schentag C, Gladman DD. Changes in fatigue in psoriatic arthritis, disease activity or fibromyalgia. Arthritis Rheum 2002;46(Suppl 9):S424 Mease PJ, Gladman DD, RitchlinCT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 2005;52:3297-89 Acknowledgements Supported by the Research program of the Ministry of health of Czech Republic: IGA MZ CR: No. 000 000 23728. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3911
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 689
SAT0265 Characteristics and Outcomes of Patients with Anca-Associated Vasculitis (AAV) in the Czech Population
Background This study describes characteristics and outcomes of AAV patients included in a nation-wide initiative collecting clinical and laboratory data since 2009. Methods Sixteen vasculitis centres (9x Nephrology, 4x Rheumatology, 2x Immunology, 1x Pediatrics) have participated in web-based data collection, consisting of retrospective data supplied at entry and prospective follow-up with a visit recorded every 3-6 months. Statistical analysis included the Kaplan-Meier method and log-rank test for survival analysis. Results A total of 681 patients (M/F 326/355, median age at diagnosis 58, range 11-89 years) were enrolled (168pts are newly diagnosed), 338 (50%) c ANCA positive, 236 p ANCA (35%), 24 (4%) ANCA negative and 72 (11%) was not investigated. The mean time from diagnosis was 71 months (range 0-475). GPA was the most common diagnosis with 58%, followed by MPA (including renal-limited form) recorded in 35% and EGPA in 4%. Cumulative organ involvement involved kidney in 83% (confirmed with renal biopsy in 72% of them), lungs in 55% joint 35% and ENT in 34%. Most (88%) pts received cyclophosphamide, azathioprine was used in 60%,mycophenolate mophetil or acid in 24%, methotrexate in 2%, 35% of patients underwent PLEX. To cope with disease activity 35 pts (4%) were treated with biological therapies, most of them (27) by rituximab. At present 512 pts are alive, pts status is assessed as complete remission in 72%, partial remission in 12%, persistent activity in 6%, primo-manifestation - new activity in 3% and relapse in 7%. Most (98%) pts. have hypertension (85% are treated by ACEi), 14 (2%) pts are post kidney Tx, 14% are dependent on dialysis. Last available VDI (Vasculitis Damage Index) ranged between 0 and 16 (median 4). The estimated 5-year survival was 81.5% (95% CI =78.1% - 84.9%) and was significantly higher in patients with ENT involvement compared to those without (p generalized > severe renal). Conclusions In the Czech population, GPA is the most common AAV, reflecting the northern European type.The disease severity at the diagnosisi is associated with higher mortality. Supported by the Czech Kidney Foundation Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5777
- 1 June 2014
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (Suppl 2) , 689
SAT0265 Characteristics and Outcomes of Patients with Anca-Associated Vasculitis (AAV) in the Czech Population
Background This study describes characteristics and outcomes of AAV patients included in a nation-wide initiative collecting clinical and laboratory data since 2009. Methods Sixteen vasculitis centres (9x Nephrology, 4x Rheumatology, 2x Immunology, 1x Pediatrics) have participated in web-based data collection, consisting of retrospective data supplied at entry and prospective follow-up with a visit recorded every 3-6 months. Statistical analysis included the Kaplan-Meier method and log-rank test for survival analysis. Results A total of 681 patients (M/F 326/355, median age at diagnosis 58, range 11-89 years) were enrolled (168pts are newly diagnosed), 338 (50%) c ANCA positive, 236 p ANCA (35%), 24 (4%) ANCA negative and 72 (11%) was not investigated. The mean time from diagnosis was 71 months (range 0-475). GPA was the most common diagnosis with 58%, followed by MPA (including renal-limited form) recorded in 35% and EGPA in 4%. Cumulative organ involvement involved kidney in 83% (confirmed with renal biopsy in 72% of them), lungs in 55% joint 35% and ENT in 34%. Most (88%) pts received cyclophosphamide, azathioprine was used in 60%,mycophenolate mophetil or acid in 24%, methotrexate in 2%, 35% of patients underwent PLEX. To cope with disease activity 35 pts (4%) were treated with biological therapies, most of them (27) by rituximab. At present 512 pts are alive, pts status is assessed as complete remission in 72%, partial remission in 12%, persistent activity in 6%, primo-manifestation - new activity in 3% and relapse in 7%. Most (98%) pts. have hypertension (85% are treated by ACEi), 14 (2%) pts are post kidney Tx, 14% are dependent on dialysis. Last available VDI (Vasculitis Damage Index) ranged between 0 and 16 (median 4). The estimated 5-year survival was 81.5% (95% CI =78.1% - 84.9%) and was significantly higher in patients with ENT involvement compared to those without (p generalized > severe renal). Conclusions In the Czech population, GPA is the most common AAV, reflecting the northern European type.The disease severity at the diagnosisi is associated with higher mortality. Supported by the Czech Kidney Foundation Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5777